Heartflow (NASDAQ:HTFL) Downgraded by Wall Street Zen to “Hold”

Wall Street Zen downgraded shares of Heartflow (NASDAQ:HTFL) from a buy rating to a hold rating in a research report released on Saturday,Wall Street Zen reports.

HTFL has been the subject of several other reports. Piper Sandler reiterated an “overweight” rating and set a $45.00 price target (up from $38.00) on shares of Heartflow in a research report on Friday, August 14th. JPMorgan Chase & Co. raised their price objective on Heartflow from $35.00 to $45.00 and gave the company an “overweight” rating in a report on Friday, August 14th. Canaccord Genuity Group raised their price objective on Heartflow from $45.00 to $56.00 and gave the company a “buy” rating in a report on Tuesday, September 22nd. UBS Group assumed coverage on shares of Heartflow in a research note on Wednesday, September 9th. They set a “neutral” rating and a $55.00 target price on the stock. Finally, Robert W. Baird set a $45.00 target price on shares of Heartflow in a report on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.25.

Heartflow Trading Down 5.1%

NASDAQ:HTFL opened at $48.29 on Friday. The stock has a 50 day moving average of $47.26 and a two-hundred day moving average of $35.26. Heartflow has a 12 month low of $20.13 and a 12 month high of $54.32. The firm has a market cap of $4.20 billion, a P/E ratio of -26.39 and a beta of 2.73.

Heartflow (NASDAQ:HTFL) last released its earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.15. The business had revenue of $64.08 million for the quarter. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%. The business’s revenue was up 47.7% compared to the same quarter last year. On average, research analysts forecast that Heartflow will post -0.75 earnings per share for the current year.

Insider Activity

In other Heartflow news, insider Campbell Rogers sold 19,682 shares of the firm’s stock in a transaction on Friday, September 18th. The stock was sold at an average price of $50.15, for a total transaction of $987,052.30. Following the completion of the sale, the insider owned 79,956 shares of the company’s stock, valued at $4,009,793.40. This trade represents a 19.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Vikram Verghese sold 16,766 shares of the firm’s stock in a transaction on Friday, September 18th. The stock was sold at an average price of $50.75, for a total value of $850,874.50. Following the sale, the chief financial officer directly owned 155,183 shares of the company’s stock, valued at approximately $7,875,537.25. This trade represents a 9.75% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 304,105 shares of company stock valued at $14,173,800. 7.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Heartflow

A number of hedge funds have recently modified their holdings of the business. GAMMA Investing LLC grew its holdings in shares of Heartflow by 75.1% during the 3rd quarter. GAMMA Investing LLC now owns 641 shares of the company’s stock worth $32,000 after purchasing an additional 275 shares during the period. IFP Advisors Inc raised its holdings in Heartflow by 844.7% in the 3rd quarter. IFP Advisors Inc now owns 803 shares of the company’s stock valued at $40,000 after buying an additional 718 shares during the period. Integrated Wealth Concepts LLC purchased a new stake in Heartflow in the 2nd quarter valued at about $53,000. Essential Partners LLC acquired a new position in Heartflow in the first quarter valued at about $57,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Heartflow in the fourth quarter valued at about $72,000.

About Heartflow

HeartFlow, Inc is a medical technology company focused on improving the diagnosis and management of coronary artery disease. The company develops software and clinical tools that use artificial intelligence, advanced image analysis and data from coronary computed tomography angiography (CCTA) scans to provide noninvasive assessments of blood flow and potential blockages in the heart.

Its principal product is the HeartFlow Analysis, which creates a personalized, three-dimensional model of a patient’s coronary arteries and can estimate the impact of blockages on blood flow.